Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study

Inclusion Criteria: * CMO in association with RP * \> 16 years of age * Unilateral or Bilateral CMO (the worse eye only will be treated - defined as the eye with a greater central macular thickness (CMT) on OCT) * No previous oral treatment for CMO for last 3 months * No previous peribulbar or intravitreal treatment for CMO in the study eye for last 3 months * No previous topical treatment for CMO in the study eye for last 1 month * Central visual impairment that in the view of the Principal Investigator is due to CMO * BCVA better than 3/60 Exclusion Criteria: * Insufficient patient cooperation or media clarity to allow adequate fundus imaging. * Evidence of visually significant vitreo-retinal traction or epiretinal membrane on OCT that in the Principal Investigator's opinion is highly likely to significantly limit the efficacy of intravitreal therapy. * History of cataract surgery within prior 3 months or cataract surgery anticipated within 6 months of starting the study. * Any anti-VEGF treatment to study eye within 3 months. * History of YAG capsulotomy performed within 3 months. * Uncontrolled Intraocular pressure (IOP) \> = 24 mmHg for ocular hypertension (on topical IOP lowering medications) * Advanced glaucoma (in the opinion of a glaucoma specialist). * Patients with active or suspected ocular or periocular infections * Patients with active severe intraocular inflammation. * Patients with a new, untreated retinal tear or detachment * Patients with a stage 3 or 4 m…